Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
Moderna and Merck say their personalized mRNA melanoma vaccine significantly reduced both cancer recurrence and spread in a late-stage trial. The treatment could reach patients as soon as next year if regulators approve it. Reuters reports: Moderna developed the vaccine with Merck and tested it together with immunotherapy drug Keytruda, a widel … ⌘ Read more